Skip to main content

Advertisement

SpringerLink
Log in

The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Object

Patients with astrocytic tumors in the central nervous system (CNS) have low survival rates despite surgery and radiotherapy. Innovative therapies and strategies must be developed to prolong survival of these patients. The alginate microencapsulation method, used to continuously release a certain cytotoxic agent in the vicinity of the tumor, is such a novel therapeutic strategy. The biological functionality of the apoptosis inducing scFv425:sTRAIL protein, which was released through the microencapsulation method, was studied in vitro. Analysis of the intracerebral biocompatibility of alginate capsules was performed by implantation of empty alginate capsules in the brain of mice.

Method

Chinese Hamster Ovary cells (CHO-K1) were recombinantly engineered to produce the single chain anti-EGFR-sTRAIL protein (scFv425:sTRAIL). The CHO-K1 producer cells were encapsulated in an alginate capsule with a semi-permeable membrane through which the scFv425:sTRAIL protein could be released.

Results

In vitro studies show maintained biological functionality of the released scFv425:sTRAIL protein. There was no immunological tissue response detectable after intracerebral implantation of the alginate capsules in mice brains.

Conclusion

Biological functionality of the produced scFv425:sTRAIL protein is maintained and intracerebral biocompatibility of the capsules is warranted. Alginate encapsulation of CHO-K1 - scFv425:sTRAIL - producer cells and subsequently their intracerebral implantation is technically feasible. This study justifies further in vivo experiments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH, Safety and antitumor activity of recombinant soluble Apo2 ligandJ Clin Invest 104: 155–162, 1999

    Article  PubMed  CAS  Google Scholar 

  2. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A, Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapyProc Natl Acad Sci USA 97: 1754–1759, 2000

    Article  PubMed  CAS  Google Scholar 

  3. Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K, A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agentsBr J Cancer 88: 298–306, 2003

    Article  PubMed  CAS  Google Scholar 

  4. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P, Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types FEBS Lett 482: 193–199, 2000

    Article  PubMed  CAS  Google Scholar 

  5. Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J, Ashkenazi A, Weller M, Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicityBiochem Biophys Res Commun 265: 479–483, 1999

    Article  PubMed  CAS  Google Scholar 

  6. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH, Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivoNat Med 5: 157–163, 1999

    Article  PubMed  CAS  Google Scholar 

  7. French LE, Tschopp J, The TRAIL to selective tumor deathNat Med 5: 146–147, 1999

    Article  PubMed  CAS  Google Scholar 

  8. Kim K, Fisher MJ, Xu SQ, El Deiry WS, Molecular determinants of response to TRAIL in killing of normal and cancer cellsClin Cancer Res 6: 335–346, 2000

    PubMed  CAS  Google Scholar 

  9. Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, Peters N, Scheurich P, Pfizenmaier K, Differential activation of TRAIL-R1 and −2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivativeOncogene 20: 4101–4106, 2001

    Article  PubMed  CAS  Google Scholar 

  10. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ: Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells Oncogene 13: 5789–5798, 2001

  11. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W, Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2Int J Cancer 109: 281–290, 2004

    Article  PubMed  CAS  Google Scholar 

  12. Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen EY, Chu Y, McDermott P, Baetge EE, Kordower JH, Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington’s diseaseNature 386: 395–399, 1997

    Article  PubMed  CAS  Google Scholar 

  13. Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM, Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNFScience 265: 1107–1110, 1994

    Article  PubMed  CAS  Google Scholar 

  14. Winn SR, Wahlberg L, Tresco PA, Aebischer P, An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in ratsExp Neurol 105: 244–250, 1989

    Article  PubMed  CAS  Google Scholar 

  15. Read TA, Farhadi M, Bjerkvig R, Olsen BR, Rokstad AM, Huszthy PC, Vajkoczy P, Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cellsCancer Res 61: 6830–6837, 2001

    PubMed  CAS  Google Scholar 

  16. Thorsen F, Read TA, Lund-Johansen M, Tysnes BB, Bjerkvig R, Alginate-encapsulated producer cells: a potential new approach for the treatment of malignant brain tumorsCell Transplant 9: 773–783, 2000

    PubMed  CAS  Google Scholar 

  17. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS, Black PM, Continuous release of endostatin from microencapsulated engineered cells for tumor therapyNat Biotechnol19: 35–39, 2001

    Article  PubMed  CAS  Google Scholar 

  18. de Vos P, Hamel AF, Tatarkiewicz K, Considerations for successful transplantation of encapsulated pancreatic isletsDiabetologia 45: 159–173, 2002

    Article  PubMed  Google Scholar 

  19. Uludag H, de Vos P, Tresco PA, Technology of mammalian cell encapsulation Adv Drug Deliv Rev 42: 29–64, 2000

    Article  PubMed  CAS  Google Scholar 

  20. de Vos P, van Hoogmoed CG, de Haan BJ, Busscher HJ, Tissue responses against immunoisolating alginate-PLL capsules in the immediate posttransplant periodJ Biomed Mater Res 62: 430–437, 2002

    Article  PubMed  CAS  Google Scholar 

  21. Wolters GH, Fritschy WM, Gerrits D, van Schilfgaarde R, A versatile alginate droplet generator applicable for microencapsulation of pancreatic isletsJ Appl Biomater 3: 281–286, 1991

    Article  PubMed  CAS  Google Scholar 

  22. Fritschy WM, Gerrits PO, Wolters GH, Pasma A, van Schilfgaarde R, Glycol methacrylate embedding of alginate-polylysine microencapsulated pancreatic isletsBiotech Histochem 70: 188–193, 1995

    PubMed  CAS  Google Scholar 

  23. Rokstad AM, Holtan S, Strand B, Steinkjer B, Ryan L, Kulseng B, Skjak-Braek G, Espevik T, Microencapsulation of cells producing therapeutic proteins: optimizing cell growth and secretionCell Transplant 11: 313–324, 2002

    PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledged F Zuiderveen, R Horn and L van Genne for their technical assistance.

Author information

Authors and Affiliations

  1. Department of Neurosurgery , University Medical Centre Groningen, University of Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 , RB, Groningen, The Netherlands

    Jos MA Kuijlen & Jan Jakob A Mooij

  2. Department of Pathology and Laboratory Medicine, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 , RB, Groningen, The Netherlands

    Bart J de Haan, Wijnand Helfrich, Jan-Freark de Boer, Douwe Samplonius & Paul de Vos

  3. Department of Neurosurgery , University Medical Centre Groningen, Hanzeplein 1, PO Box 30.001, 9700, RB Groningen, The Netherlands

    Jos MA Kuijlen

Authors
  1. Jos MA Kuijlen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bart J de Haan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wijnand Helfrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan-Freark de Boer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Douwe Samplonius
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jan Jakob A Mooij
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paul de Vos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jos MA Kuijlen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuijlen, J.M., de Haan, B.J., Helfrich, W. et al. The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors. J Neurooncol 78, 31–39 (2006). https://doi.org/10.1007/s11060-005-9071-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-005-9071-3

Keywords

Search

Navigation